<DOC>
	<DOCNO>NCT01028222</DOCNO>
	<brief_summary>The purpose study determine whether nilotinib efficacious treatment metastatic and/or inoperable melanoma harbor c-Kit mutation .</brief_summary>
	<brief_title>A Study AMNN107 Treatment Metastatic and/or Inoperable Melanoma Harboring c-Kit Mutation</brief_title>
	<detailed_description>This trial begin multi-center , randomize , Phase III , control trial nilotinib v ( DTIC ) dacarbazine ass efficacy safety nilotinib ( 400 mg bid ) patient c-Kit mutated metastatic and/or inoperable melanoma . The study open patient mucosal acral melanoma . Due substantial difficulty identify recruit eligible patient , trial design alter randomize , two-arm , Phase III study single-arm , Simon two-stage Phase II study protocol Amendment 2 ( 27-Jul-2011 ) . While original protocol require recruitment 120 patient , amendment require study recruit 41 patient ( patient randomize nilotinib prior Amendment 2 count total , randomized dacarbazine ( DTIC ) DTIC ) . Patients randomize DTIC allow cross-over nilotinib , either immediately time progression .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<criteria>1 . Histologically confirm mucosal acral 2 . Presence cKit mutation exon 9 , 11 13 , mutation Y822D mutation D820Y , Y823D exon 17 , confirm central laboratory 3 . Stage III unresectable stage IV disease 4 . The presence one measurable lesion detect radiological photographic method assess accord RECIST 1.0 . Lesions must size least 10mm long diameter ( use slice thickness 5 mm ) double slice thickness consider target lesion . Target lesion select previously irradiate field unless clear evidence progression 5. WHO performance status 0 2 1 . CKit mutation exon 17 ( except mutation D820Y , Y822D Y823D ) exon allow inclusion criterion 2 . Patients cKit amplification mutation 3 . Patients history brain metastases 4 . Patients prior treatment TKIs 5 . Patients receive medication herbal extract interfere nilotinib metabolism discontinue time baseline visit 6 . Acute chronic liver renal disease consider unrelated melanoma Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Melanoma</keyword>
	<keyword>AMN107</keyword>
	<keyword>c-Kit</keyword>
	<keyword>c-Kit mutate metastatic and/or inoperable melanoma</keyword>
</DOC>